Aziz Mottiwala - Aug 24, 2022 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Commercial Officer
Signature
/s/ Leonard M. Greenstein, Attorney-in-Fact
Stock symbol
TARS
Transactions as of
Aug 24, 2022
Transactions value $
$0
Form type
4
Date filed
8/26/2022, 04:25 PM
Previous filing
Mar 11, 2022
Next filing
Nov 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise $48.5K +4.42K +8.59% $10.99 55.8K Aug 24, 2022 Direct F1
transaction TARS Common Stock Options Exercise $347 +772 +1.38% $0.45* 56.6K Aug 24, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Employee Stock Option (right to buy) Options Exercise -$48.5K -4.42K -29.46% $10.99 10.6K Aug 24, 2022 Common Stock 4.42K $10.99 Direct F2
transaction TARS Employee Stock Option (right to buy) Options Exercise -$347 -772 -100% $0.45* 0 Aug 24, 2022 Common Stock 772 $0.45 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 470 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 725 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.
F2 Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020.
F3 Option granted under the Plan. 25% of the option shares vested and became exercisable on July 27, 2019 and the remaining option shares vest and become exercisable in 36 equal monthly installments thereafter.